poisar

Stock

Intensity Therapeutics, Inc. INTS

$4.00-3.85%

Overview

INTS market data

Price History

INTS price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$8.56
Diluted earnings per share over the trailing twelve months.
Beta
2.97
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$3.51 – $43.50
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $11.6M · P/B 2.07.

Company News

3 captured
Intensity Therapeutics Q2 EPS $(1.11), InlineBenzinga · Aug 11, 2026, 11:52 AM
8-K filing — INTENSITY THERAPEUTICS, INC. (INTS)SEC EDGAR · Aug 11, 2026, 11:40 AM
Intensity Therapeutics Administers New Patients With INT230‑6 In INVINCIBLE‑4 Switzerland Study; Trial Evaluates pCR Rates Vs Null Hypothesis Across SOC And INT230‑6+SOC CohortsBenzinga · Jul 15, 2026, 11:48 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock